The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2021 May 1;19(5):541-565. doi: 10.6004/jnccn.2021.0022.
Al B Benson1, Michael I D'Angelica2, Daniel E Abbott3, Daniel A Anaya4, Robert Anders5, Chandrakanth Are6, Melinda Bachini7, Mitesh Borad8, Daniel Brown9, Adam Burgoyne10, Prabhleen Chahal11, Daniel T Chang12, Jordan Cloyd13, Anne M Covey2, Evan S Glazer14, Lipika Goyal15, William G Hawkins16, Renuka Iyer17, Rojymon Jacob18, R Kate Kelley19, Robin Kim20, Matthew Levine21, Manisha Palta22, James O Park23, Steven Raman24, Sanjay Reddy25, Vaibhav Sahai26, Tracey Schefter27, Gagandeep Singh28, Stacey Stein29, Jean-Nicolas Vauthey30, Alan P Venook19, Adam Yopp31, Nicole R McMillian32, Cindy Hochstetler32, Susan D Darlow32
Author information
1Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
2Memorial Sloan Kettering Cancer Center.
3University of Wisconsin Carbone Cancer Center.
4Moffitt Cancer Center.
5The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
6Fred & Pamela Buffett Cancer Center.
7The Cholangiocarcinoma Foundation.
8Mayo Clinic Cancer Center.
9Vanderbilt-Ingram Cancer Center.
10UC San Diego Moores Cancer Center.
11Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
12Stanford Cancer Institute.
13The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
14St. Jude Children's Research HospitalThe University of Tennessee Health Science Center.
15Massachusetts General Hospital Cancer Center.
16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
17Roswell Park Comprehensive Cancer Center.
18O'Neal Comprehensive Cancer Center at UAB.
19UCSF Helen Diller Family Comprehensive Cancer Center.
20Huntsman Cancer Institute at the University of Utah.
21Abramson Cancer Center at the University of Pennsylvania.
22Duke Cancer Institute.
23Fred Hutchinson Cancer Research CenterSeattle Cancer Care Alliance.
24UCLA Jonsson Comprehensive Cancer Center.
25Fox Chase Cancer Center.
26University of Michigan Rogel Cancer Center.
27University of Colorado Cancer Center.
28City of Hope National Medical Center.
29Yale Cancer Center/Smilow Cancer Hospital.
30The University of Texas MD Anderson Cancer Center.
31UT Southwestern Simmons Comprehensive Cancer Center; and.
32National Comprehensive Cancer Network.
Abstract
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.